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1. Introduction 
Ovarian cancer is the fifth most common cancer among women and approximately 
200,000 women are diagnosed as ovarian cancer every year in the world (Parkin et al., 
2005). Platinum-containing chemotherapeutic agents such as cisplatin (cis-
diamminedichloroplatinum II) and carboplatin have been most frequently used for the 
treatment of ovarian cancer. These platinum compounds specifically react with guanine 
residues in DNA to form interstrand and intrastrand cross-links in DNA, known as DNA-
adducts. This interferes with mitosis of cancer cells and causes cell death. However, ovarian 
cancer cells can become resistant to cisplatin and the majority of patients develop cisplatin-
resistant disease (Giaccone 2000; Hennessy et al., 2009; Kartalou & Essigmann 2001), and as 
a result, most ovarian cancers relapse. Paclitaxel (taxol) and two analogues of camptothecin, 
irinotecan and topotecan, are the drugs most commonly administered to platinum-resistant 
ovarian cancer patients. Paclitaxel (taxol) binds to -tubulin and stabilizes microtubule 
structure, which causes a G2/M block in the cancer cell cycle. Irinotecan, also known as 
CPT-11 (7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxy camptothecin) and 
topotecan (10-hydroxy-9-dimethylaminomethyl-(S)-camptothecin) inhibit topoisomerase I 
by resealing DNA breaks, which results in the inhibition of cancer cell growth (Bookman et 
al., 1998; Swisher et al., 1997). However, the survival rate for relapsed patients is low; Thus, 
there is an urgent need for more effective chemotherapeutic approaches for ovarian cancer 
treatment. We have previously reported that some ovarian cancer cell lines are remarkably 
sensitive to vitamin K2 (Shibayama-Imazu et al, 2003, 2006, 2008). In this review, strategies 
for developing chemotherapeutic agents for ovarian cancer are described and vitamin K2 is 
proposed as a promising chemotherapeutic agent for ovarian cancer. 
2. Effect of vitamin K2 on cancer cells 
Natural forms of vitamin K such as vitamin K1 (phylloquinone) and vitamin K2 
(menaquinones, MK) are cofactors for the post-translational -carboxylation of glutamate 
residues in vitamin K-dependent proteins (Fig. 1). Vitamin K is mainly used as a hemostatic 
agent because coagulation factors VII, IX, and X, which are critical to blood coagulation, are 
vitamin K-dependent proteins. In addition, vitamin K2 has anti-cancer activity, whereas 
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vitamin K1 does not. This difference arises from structural differences in the side chains 
attached to the parent ring of vitamin K. 
2.1 Structures and fundamental properties of vitamin K 
The parent ring structure of vitamin K is 2-methyl-1,4-naphthoquinone (menadione), which is 
also known as vitamin K3 (Fig. 1). Vitamin K3 does not occur naturally and causes oxidative 
stress in both normal and cancer cells and is toxic to the liver. There are few successful clinical 
applications of vitamin K3. Vitamin K1 has a phythyl side chain at the 3 position of vitamin K3 
and is present mainly in green vegetables. Vitamin K1 is converted to vitamin K2 in animals 
and humans (Thijssen & Drittij-Reijnders, 1996); vitamin K2 has isoprenoid side chains of 
various lengths attached to the 3 position of the vitamin K3 ring structure. The different forms 
of vitamin K2, menaquinone-n (MK-n), are categorized according to the number of repeating 
isoprenoid residues in the side chain. The most common form of vitamin K2 in animals is 
menaquinone-4 (MK-4), which has four isoprenoid residues as its side chain. MK-4 is the most 
biological active form of the vitamin and is produced by intestinal bacteria. Long chain 
menaquinones, MK-7 to MK-10, are synthesized by bacteria and are present in fermented 
products such as cheese (MK-8 and MK-9) and East Asian fermented soybean products, such 
as natto and miso (Shearer et al., 1996; Schurgers & Vermeer, 2000).  
 
 
Fig. 1. Chemical Structures of vitamin K 
Naturally occurring vitamin K1 contains a phytyl group, and vitamin K2 has a repeating 
isoprenoid group at the 3 position of the vitamin K3 menadione ring. In animals, the most 
common and most biologically active form of vitamin K2 is MK-4, which has four 
isoprenoid residues (n = 4). Unlike vitamin K1, vitamin K2 has anti-cancer activity in 
addition to its critical role in blood coagulation and bone metabolism. The isoprenyl side 
chain of vitamin K2 contributes to its unique anti-cancer activity.  
2.2 Growth inhibitory activity of vitamin K2 on cancer cells 
We initially demonstrated vitamin K2-induced differentiation in human leukemia cells 
which was unrelated to its clinical role in blood coagulation and bone metabolism (Sakai I, 
1994). Inhibition of cancerous cell growth and induction of apoptosis by vitamin K2 has 
subsequently been observed in a variety of human cancer cell lines, including liver 
(Nishikawa et al., 1995; Otsuka et al., 2004), pancreatic (Shibayama-Imazu et al., 2003), 
ovarian (Shibayama-Imazu et al., 2003, 2006, 2008), lung (Yoshida et al., 2003; Yokoyama et 
al., 2005), stomach (Tokita et al., 2006), breast (Wu et al., 1993), and leukocyte (Yaguchi, 
1997). The growth-inhibitory effects of vitamin K2 on various human cancer cell lines are 
listed in Table 1. Vitamin K2 has almost no effect on normal bone marrow cells (Miyazawa 
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et al., 2001), and inhibition of cancerous cell growth was not observed with vitamin K1. 
Therefore, the side chain of vitamin K2 may be important for the anti-cancer activity of 
vitamin K2. The anti-cancer activity of isoprenoids is known to depend on the length of the 
polyprenyl alcohol side chain; polyprenoids with a geranylgeranyl group or a 
geranylisopropyl group have the most potent anticancer activity (Ohizumi et al., 1995). 
Vitamin K2 MK-4 has a geranylgeranyl side chain and is commonly used for the treatment 
of a variety of cancer cells. In this review, vitamin K2 MK-4 is denoted simply as vitamin K2. 
 
 
Table 1. IC50 values for vitamin K2 in various cancer cell lines. IC50 is defined as the 
concentration of vitamin K2 that inhibits cell growth by 50%. The values for SW626 and 
OVCAR3 were estimated from previously published results (Shibayama-Imazu et al., 2008). 
Clinical trials using vitamin K2 that were conducted successfully for leukemia and liver 
cancer patients are indicated by boxes. 
3. Induction of apoptosis in ovarian cells by vitamin K2 
Inhibition of cell growth is a good indicator of the induction of apoptosis in cancer cells by 
chemical agents. A comparison of the inhibition of the growth of various cancer cells by 
vitamin K2 showed that an ovarian cancer cell line PA-1 is the most sensitive to vitamin K2. 
A steroid orphan receptor TR3/Nur77, which regulates cell proliferation and apoptosis, is 
responsible for the induction of apoptosis in ovarian cancer PA-1 cells by vitamin K2. 
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3.1 Growth inhibition of ovarian cancer cells by vitamin K2 
We observed that apoptosis is readily induced in some ovarian cancer cell lines by low 
concentrations of vitamin K2 (Shibayama-Imazu et al, 2003; 2006). Figure 2 shows that 
vitamin K2 is a potent inhibitor of the growth of human ovarian cancer PA-1 cells, with an 
IC50 of 5.0 + 0.7 M. The IC50 value for PA-1 cells is the lowest observed for cancer cell lines 
treated with vitamin K2, indicating that PA-1 cells are the most sensitive to vitamin K2 
(Table 1). In contrast to PA-1 cells, SK-OV-3 cells were resistant to vitamin K2 and no 
significant growth inhibition was observed (Fig. 2). PA-1 and SK-OV-3 cells were used as 
vitamin K2-sensitive and vitamin K2-resistant cells, respectively, in order to examine the 
mechanism of apoptosis induction by vitamin K2. 
 
 
Fig. 2. Effects of vitamin K2 on the growth of human ovarian cancer PA-1 and SK-OV-3 cells. 
Cell proliferation was determined using the XTT assay 96 h after treatment with various 
concentrations of vitamin K2. Each value is represented as mean + SD of the results from 
three independent experiments. Vitamin K2-sensitive PA-1(●); vitamin K2-resistant SK-OV-
3 (○). [Reproduced with permission from Fig. 1 of Shibayama-Imazu et al., 2008.] 
3.2 Mechanism of the induction of apoptosis by vitamin K2  
The induction of apoptosis by vitamin K2 in vitamin K2-sensitive ovarian cancer PA-1 cells 
proceeds slowly. Fragmented nucelosomes were released into the cytosolic fraction 24 h 
after the start of incubation of PA-1 cells with 30 M vitamin K2, and increased until at least 
72 h after the start of incubation (Fig. 3A). After 72 h, the induction of apoptosis was evident 
in approximately 35% of PA-1 cells, as determined by counting apoptotic cells with 
condensed and fragmented nuclei stained with Hoechst 33342 (Shibayama-Imazu et al., 
2008). The slow rate of apoptosis is one of the characteristic features of vitamin K2-induced 
apoptosis, compared to apoptosis induced by conventional anticancer agents such as 
camptothecin and etoposide, and by geranaylgeraniol (Masuda et al., 2000; Shibayama-
Imazu et al., 2003). Mitochondria play a crucial role in the induction of apoptosis by various 
apoptotic agents. Cytochrome c released from mitochondria forms a complex with Apaf-1 
and activates procaspase 9, which activates a downstream caspase cascade. Once the 
caspase cascade has been triggered, nucleases are activated to induce apoptotic chromatin 
condensation and DNA fragmentation. The release of cytochrome c in PA-1 cells was 
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detected 48 h after treatment with 30 M vitamin K2 and the release increased sharply 72 h 
after the treatment (Fig. 3B). 
 
 
 
 
Fig. 3. Induction of apoptosis in ovarian cancer PA-1 and SK-OV-3 cells by vitamin K2. (A) 
Both vitamin K2-sensitive PA-1 (●) and vitamin K2-resistant SK-OV-3 (○) cells were treated 
with 30 M of vitamin K2 for various times. Each value is represented as mean + SD of the 
results from three independent experiments. The percentage of apoptotic cells that 
contained condensed and fragmented chromatin was quantified after staining with Hoechst 
33342 as described previously (Shibayama-Imazu et al., 2008). (B) The panel shows 
immunoblotting analysis of cytochrome c released from mitochondria into the cytoplasm of 
PA-1 cells that had been treated with 30 M vitamin K2 (Shibayama-Imazu et al., 2008). 
[Reproduced with permission from Fig. 6 of Shibayama-Imazu et al., 2008.] 
3.3 Accumulation of TR3/Nur77 in mitochondria after treatment of PA-1 cells with 
vitamin K2 
A steroid orphan receptor TR3/Nur77 is overexpressed in various cancer cells lines, including 
ovarian (Holmes et al., 2002), lung (Li et al., 1998), prostate (Li et al., 2000), colon (Cho et al., 
2007), pancreatic (Chintharlapalli et al., 2005), bladder (Chintharlapalli et al., 2005) and 
stomach (Wu et al., 2002). The expression of TR3/Nur77 is rapidly induced during cancer cell 
apoptosis triggered by various apoptotic agents, such as phorbol ester 12-O-tetradecanoyl 
phobol-13-acetate (Li et al., 2000), etoposide (Li et al., 2000), cytosporone B (Liu et al., 2010), 
and the synthetic retinoid 6-[3-(1-admantyl)]-4-hydroxyphenyl]-2-naphthalene carboxylic acid 
(CD437, Holmes et al., 2004). TR3/Nur77 translocates from the nucleus to mitochondria in 
response to these apoptosis inducers, with the exception of CD437 (Li et al., 2000). TR3/Nur77 
binds to Bcl-2 which switches the function of Bcl-2 from protection to the induction of 
www.intechopen.com
 
Ovarian Cancer – Clinical and Therapeutic Perspectives 
 
264 
cytochrome c release from the mitochondria, resulting in the induction of apoptosis (Li et al., 
2000). For CD437, the levels of TR3/Nur77 in the nuclei of various pancreatic cancer cells were 
increased by treatment with this agent, although translocation of TR3/Nur77 from the nuclei 
to the mitochondria was not observed (Chintharlapalli et al., 2005).  
 
 
Fig. 4. Immunoblotting analysis of TR3/Nur77 in vitamin K2-sensitive PA-1 cells and 
vitamin K2-resistant SK-OV-3 cells. Both vitamin K2-sensitive PA-1 and vitamin K2-resistant 
SK-OV-3 cells were treated with 30 M of vitamin K2 for 0 h, 24 h, 48 h, and 72 h. 
TR3/Nur77 in the cell lysates (A) and in the heavy mitochondrial fractions (B) were detected 
by immunoblotting using rabbit TR3/Nur77-specific polyclonal antibody (Shibayama-
Imazu et al., 2008). Two immunostained bands were detected under our electrophoretic 
conditions as previously reported (Chintharlapalli et al., 2005). The more slowly migrating 
minor band is phosphorylated TR3/Nur77 (Pekarsky et al., 2001). The intensities of the 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) band and the cytochrome oxidase 
subunit Ⅳ (OX) band confirmed that an equal amount of cell lysate proteins and heavy 
mitochondrial fraction proteins, respectively, were loaded in each lane. [Reproduced with 
permission from Fig. 3 and Fig. 6 of Shibayama-Imazu et al., 2008.] 
The level of TR3/Nur77 in vitamin K2-sensitive PA-1 cells was approximately four-fold 
higher than that in vitamin K2-resistant SK-OV-3 cells (Fig. 4A). The level of TR3/Nur77 in 
the cell lysate of PA-1 cells increased markedly in a time-dependent manner after treatment 
with vitamin K2. In contrast, the level of TR3/Nur77 in the cell lysate of vitamin K2-
resistant SK-OV-3 cells was very low and was not significantly affected by treatment with 
vitamin K2. The TR3/Nur77 level in the cell lysate of SK-OV-3 cells did not reach the level 
observed in untreated PA-1 cells, even 72 h after the start of the treatment.  
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In the heavy mitochondrial fraction, which is composed mostly of mitochondria, the level of 
TR3/Nur77 increased sharply 48 h and 72 h after the start of the treatment of PA-1 cells with 
vitamin K2 (Fig. 4B). The percentage of apoptotic cells increased in parallel with the increase 
in TR3/Nur77 in the heavy mitochondrial fraction of PA-1 cells (Fig. 3A). In contrast, the 
level of TR3/Nur77 in the heavy mitochondrial fraction of vitamin K2-resistant SK-OV-3 
cells was unchanged by vitamin K2 treatment (Fig. 4B). Immunofluorescence staining of PA-
1 cells during vitamin K2-induced apoptosis indicates that the amounts of TR3/Nur77 
present in both mitochondria and nuclei as well as in the cytosolic fraction increased after 
vitamin K2 treatment (Shibayama-Imazu et al., 2008). This suggests that TR3/Nur77 
migrated directly from the cytoplasm to the mitochondria and no translocation from the 
nucleus to mitochondria occurred. It should be noted that this effect of vitamin K2 on 
ovarian cancer PA-1 cells is unique and different from that of apoptosis-inducing agents 
such as etoposide (Li et al., 2000) and cytosporone B (Liu et al., 2010) which cause 
translocation of TR3/Nur77 from the nuclei to the mitochondria. 
4. Strategy for the improvement of chemotherapy of ovarian cancer 
Combination treatments with agents that sensitize ovarian cancer cells to platinum 
compounds are an efficient strategy for overcoming chemoresistance acquired by ovarian 
cancer cells. Cancer cell survival signals can be inhibited by chemical agents, or ovarian 
cancer cells can be sensitized to platinum chemotherapeutic agents by preventing the repair 
of platinum-DNA adducts. A further method is to find chemical agents that induce 
apoptosis in ovarian cancer cells by a different mechanism from platinum compounds and 
may therefore exert synergistic apoptotic effects. 
4.1 Inhibition of survival signals  
The balance between cellular survival and induction of apoptosis determines the sensitivity 
of cancer cells to chemotherapeutic drugs. Therefore, blocking survival cascade signals or 
enhancing apoptosis-inducing signals enhances the sensitivity of ovarian cancer cells to 
chemotherapeutic agents (Vivanco & Sawyers, 2002). Topotecan, an inhibitor of 
topoisomerase I, inhibits Akt kinase activity in cisplatin-resistant ovarian cancer Caov-3 cells 
(Tsunetoh et al., 2010). The PI3K-Akt survival cascade signal in cisplatin-resistant ovarian 
cancer cells is inhibited by treatment with a combination of topotecan and cisplatin, which 
enhances the sensitivity to cisplatin in vitro and in vivo (Tsunetoh et al., 2010). The flavonoid 
compound, kaempherol, sensitizes ovarian cancer OVCAR-3 cells to cisplatin by down 
regulation of cMyc, which is involved in proliferation and is commonly activated in human 
cancer cells (Jung et al., 2008; Luo et al., 2010). Treatment of cisplatin resistant A2780CP 
ovarian cancer cells with a polyphenol, curcumin (diferulonyl methane), derived from the 
rhizomes of turmeric Curcuma longa, down regulated the expression of cMyc and pro-
survival proteins such as Bcl-XL and Mcl-1, leading to cisplatin sensitization (Yallapu, 2010). 
Topotecan, kaempherol, and curcumin therefore warrant further investigation as potential 
therapeutic agents for ovarian cancer. 
4.2 Inhibition of platinum-DNA adduct repair 
Inhibitors of DNA synthesis, such as gemcitabine (Touma et al., 2006), cytarabine (Swinnen 
et al., 2008), hydroxyurea (Raymond et al., 2001), and aphidicolin (Sargent et al., 1996), are 
able to inhibit the repair process of platinum-DNA adducts and have been used to increase 
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sensitivity to chemotherapeutic platinum compounds. A phase II study using carboplatin 
followed by gemcitabine and paclitaxel for the treatment of ovarian cancer patients showed 
an improvement in therapeutic efficacy (Harries et al., 2004). However, the pulmonary 
toxicity observed as a side effect of this treatment still needs to be addressed. 
The histone deacetylase inhibitor panobinostat, which affects the expression of various 
genes, showed synergistic cytotoxic effects in conjunction with conventional 
chemotherapeutic agents including carboplatin on ovarian cancer cell lines (Budman et al., 
2010).  
Arsenic trioxide inhibits UV-induced DNA repair processes (Hartwig et al., 1997), and also 
showed additive cytotoxic effects with cisplatin for human ovarian carcinoma cell lines in 
vitro (Uslu et al., 2000). Arsenic trioxide was successfully used for the treatment of all-trans 
retinoic acid resistant acute promyelocytic leukemia (Soignet et al., 1998), which suggests 
that it may be successful in treating cisplatin-resistant ovarian cancer patients. 
4.3 Induction of apoptosis in cancer cells by activating the TR3/Nur77 gene 
Indole -3-carbinol (I3C), contained in cruciferous vegetables such as broccoli, cabbage, and 
cauliflower, and its dimeric product 3,3’-diindolylmethane (DIM) are nontoxic, natural 
compounds with anticancer activities. DIM and its analogues increase the levels of 
TR3/Nur77 and induce apoptosis in various cancer cell lines including colon, pancreas, 
prostate, and breast cancer cells (Banerjee et al., 2009; Cho et al., 2007). Pancreatic cancer 
cells with acquired resistance to chemotherapeutic drugs, such as cisplatin, oxaliplatin, and 
gemcitabin, were sensitized by pretreatment with DIM (Banerjee et al., 2009). Compounds 
that activate the TR3/Nur77 gene and induce apoptosis in cancer cells are proposed as a 
new category of chemotherapeutic drugs, and include an analogue of cytosporone B (Liu et 
al., 2010) and 1,1-bis(3'-indolyl)-1-(p-substituted phenyl) methanes (C-substituted DIMs, 
Chintharlapalli et al., 2005). Acetylshikonin and its derivative 5,8-diacetoxyl-6-(1'-acetoxyl-
4'-methyl-3'-pentenyl)-1,4-naphthaquinones (SK07) increased the level of TR3/Nur77 
through posttranscriptional regulation, and induced apoptosis in various cancer cell lines 
including lung and cervical cancer cells (Liu et al., 2008). The positive correlation of the 
expression of the TR3/Nur77 subfamily member Nor-1 with survival rates of diffuse large 
B-cell lymphoma patients indicates the importance of TR3/Nur77 as a target for anti-cancer 
agents (Shipp et al., 2002). The importance of TR3-Nur77 as a therapeutic target of ovarian 
cancer is also demonstrated by the fact that low expression of TR3/Nur77 in tissue samples 
obtained from various cancer patients is significantly associated with metastasis of primary 
solid cancers (Ramaswamy et al., 2003). 
We discovered that some ovarian cancer cell lines, such as PA-1 cells, are sensitive to 
vitamin K2 and apoptosis induced by stimulation of TR3/Nur77 synthesis and its 
accumulation in mitochondria (Fig. 5). Small interfering RNA (siRNA) directed against TR3-
Nur77 (siRNA-TR3/Nur77) caused a marked decrease in the levels of TR3/Nur77 in the 
lysate of PA-1 cells. When ovarian cancer PA-1 cells after transfection with siRNA-
TR3/Nur77 were treated with vitamin K2, the marked increase in the levels of TR3/Nur77 
observed by vitamin K2 without siRNA-TR3/Nur77 was almost completely abolished 
(Shibayama-Imazu et al., 2008). Induction of apoptosis by vitamin K2 was also significantly 
inhibited by transfection of PA-1 cells with siRNA-TR3/Nur77. Furthermore, 
cycloheximide, an inhibitor of protein synthesis, prevented the increase in TR3/Nur77 
levels, its accumulation in the mitochondria, and the induction of apoptosis in PA-1 cells 
caused by vitamin K2 treatment (Shibayama-Imazu et al., 2008). These results indicate that 
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the synthesis of TR3/Nur77 and its accumulation in mitochondria are required for the 
induction of apoptosis in PA-1 cells by vitamin K2 and also suggest that an increase in the 
level of TR3/Nur77 could be the cause of sensitivity to the induction of apoptosis in PA-1 
cells by vitamin K2 (Fig. 5). 
 
 
Fig. 5. A model for the induction of apoptosis in vitamin K2-sensitive ovarian cancer cells. 
The levels of TR3/Nur77 in vitamin K2-sensitive ovarian cancer cells are increased after 
treatment with vitamin K2. TR3/Nur77 synthesized in the cytoplasm migrates to the 
mitochondria and binds to Bcl-2, which protects the cell from apoptosis. Interaction of 
TR3/Nur77 with Bcl-2 induces a conformational change in Bcl-2, triggering the release of 
cytochrome c, which activates the caspase cascade and thus induces apoptosis. siRNA-
TR3/Nur77 causes degradation of TR3/Nur77 mRNA and cycloheximide inhibits the 
protein synthesis of TR3/Nur77, both leading to inhibition of the induction of apoptosis by 
vitamin K2. 
A combination of vitamin K2 and conventional chemotherapeutic agents for ovarian cancer, 
such as cisplatin and etoposide, which induce apoptosis by different mechanisms, might have 
additive or synergistic apoptotic effects on ovarian cancer cells. In addition, pretreatment with 
vitamin K2 or combination treatment with conventional chemotherapeutic agents could be 
effective for overcoming chemoresistance in ovarian cancer cells.  
5. Vitamin K2 as a promising chemotherapeutic agent for ovarian cancer  
Vitamin K2 induces apoptosis in blastic cells from patients with myelodysplastic syndrome 
(Nishimaki et al., 1999; Yaguchi et al., 1998) and has been successfully used in the clinical 
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treatment of patients with this disorder (Miyazawa et al., 2000; Takami et al., 1999; Yaguchi 
et al., 1998, 1999). Oral administration of vitamin K2 with retinoic acid to a patient with 
relapsed acute promyelocytic leukemia resulted in complete remission (Fujita et al., 1998). In 
addition, oral administration of vitamin K2 also had a suppressive effect on the recurrence 
of hepatocellular carcinoma and improved patient survival rate (Habu et al., 2004; Mizuta et 
al., 2006; Tamori et al., 2007; Yoshiji et al., 2009). A recent cohort study indicates that cancer 
incidence and mortality were significantly decreased by dietary intake of vitamin K2 from 
food sources (Nimptsch et al., 2010). Vitamin K2 is also used clinically as a drug for 
osteoporosis in Asian countries such as Japan, Korea, and Thailand, because it also has a 
significant effect on bone fracture prevention (Cockayne et al., 2006; Olson, 2000; Shiraki et 
al., 2000). This is because calcium-binding proteins such as osteocalcin and calbindin, which 
are involved in calcium uptake and bone mineralization, are vitamin K-dependent proteins. 
A further cohort study indicated that the relative risk of coronary heart disease was also 
reduced by dietary intake of vitamin K2 (Geleijne et al., 2004). This may be because vitamin 
K-dependent proteins are associated with vascular repair processes (Benzakour & Kanthou, 
2000) and the prevention of vascular calcification (Shanahan et al, 1998). No side effects from 
vitamin K2 therapy were observed in any of these clinical studies; even vitamin K2 dosages 
in excess of 40 mg/day did not cause any side effects associated with hypercoagulable states 
(Shiraki et al., 2000), demonstrating its excellent safety profile. However, it is unknown why 
some ovarian cancer cell lines are resistant to vitamin K2. It may be possible to overcome 
vitamin K2 resistance by using it in combination with other agents that increase the level of 
TR3/Nur77 in cancer cells, such as DIM, cytosporone B, and the shikonin derivative SK07. 
SK07 stimulates the protein synthesis of TR3/Nur77 even in cervical cancer HeLa cells, in 
which the basal expression level of TR3/Nur77 is low (Liu et al., 2008). Further pre-clinical 
and clinical evaluation of vitamin K2 is required for its use in chemotherapy for ovarian 
cancers.  
6. Conclusion  
Several ovarian cancer cell lines are sensitive to vitamin K2; the IC50 value of the most vitamin 
K2-sensitive ovarian cancer PA-1 cells is as low as 5 M. Apoptosis is induced in PA-1 cells 
through the stimulation of TR3/Nur77 synthesis and its accumulation in mitochondria, which 
results in the release of cytochrome c and activation of the caspase cascade (Fig. 5). Because 
this mechanism is different from those of conventional chemotherapeutic agents for ovarian 
cancer such as cisplatin and etoposide, the present study demonstrates a new method for 
increasing the sensitivity of cisplatin resistant ovarian cancer cells to chemotherapy. Moreover, 
our observation suggests that the combination of vitamin K2 with cisplatin or etoposide may 
potentially be effective for the treatment of ovarian cancers. None of the clinical trials using 
high doses of vitamin K2 have recorded side effects from the treatment, and oral 
administration of vitamin K2 has already been successfully used for the treatment of acute 
promyelocytic leukemia and haepatocellular carcinoma (Table 1). We therefore propose 
vitamin K2 as a useful chemotherapeutic agent for ovarian cancer.  
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